OCProDx
Strategic planning for commercialisation of a multiplexed protein diagnostic (Dx) blood test for Organ-Confined Prostate cancer: OCProDx
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0OCProDx project word cloud
Explore the words cloud of the OCProDx project. It provides you a very rough idea of what is the project "OCProDx" about.
Project "OCProDx" data sheet
The following table provides information about the project.
| Coordinator |
ATTUROS LIMITED
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://www.atturos.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-01-01 to 2016-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ATTUROS LIMITED | IE (LIMERICK CLARE) | coordinator | 50˙000.00 |
Map
Project objective
In Europe over 400,000 (US >250,000, globally >1M) men are diagnosed with prostate cancer every year and well over half will have intermediate to low risk disease. The vast majority of these men would benefit from active surveillance (AS) - monitoring of disease progression before treatment. But most are treated by surgery, radiation or drugs because existing diagnostic tools do not adequately support the AS vs. treatment decision. For those men on AS the tests do easily allow long term repeated monitoring. The over-treatment of prostate cancer is a widely acknowledged and serious issue: the side effects of treatment are often worse than the disease itself and impact negatively on quality of life. We have discovered, developed and patented a blood protein signature that can discriminate between disease that remains confined to the prostate or has spread beyond it. This multiplexed protein signature, the OCProDx test, has the capacity to support at least three key patient decisions. i) for men newly diagnosed with prostate cancer: the decision between AS and treatment; ii) for men on AS: whether to treat or not, and iii) for those to be treated: which treatment may be the best option. The OCProDx test, will be licensed to a newly founded UCD Spin out company 'Atturos’. The market size is very large, the need significant and the estimated gross profit margin very attractive. We believe there is a compelling opportunity to grow Atturos to develop OCProDx within a commercial setting and deliver it to market. In so doing, Atturos will grow rapidly to create high value EU employment opportunities that will be global in reach. Well-resourced laboratory based studies are currently underway to consolidate the technical performance of OCProDx and validate its clinical performance. In this proposal we seek to engage with key external consultants to develop and produce a detailed business plan for Atturos to commercialise and monetise OCProDx.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OCPRODX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "OCPRODX" are provided by the European Opendata Portal: CORDIS opendata.